Ronnie Moas Downgrades Kite Pharma, Sees $100 Stock Price Through 2018
Deutsche Bank Offers Takeaways Following Meeting With FireEye CFO
Why Baidu's Margins Are Still A Concern
Whiting Petroleum's Results Were Merely 'Lackluster,' Says Iberia's Eli Kantor
4 Key Risks Goldman Sees At Twitter
Goldman Sees 'Significant' Challenges At HP
SolarCity Might Miss Guidance This Quarter, New Checks Show
BMO Thinks Valeant's Structure Is 'Questionable,' Says Investigation May Be Needed To Resolve Uncertainty
Goldman: Memorial Resource Development Has 28% Upside
1 Thing Pushing FitBit Stock Up
Cowen: In Biotech Earnings We Trust
Social Media Beat: What Experts And The Crowd Think Of Biotechs, GE And Tesla
Why IBM Needs Growth To Turn Around
Xenia Hotels: The Hottest Way To Play U.S. Lodging?
4 Different Ways To Invest In Cybersecurity
Time To Buy Micro-Cap CymaBay Therapeutics: H.C. Wainwright
How ETFs Work & Why They Differ From Mutual Funds
An Underrated Cost Savings King With A 2016 Outlook
Campbell Soup: A Return To Growth In 2016
Can Schlumberger Outperform The Market? Citi Thinks So